6 February 2024
Physiomics plc
("Physiomics" or the "Company")
Options Award
Physiomics plc (AIM: PYC), announces an
award of share options (the "Options") over
ordinary shares of 0.4p each in the Company ("Ordinary
Shares"). The Company considers that it is important to
incentivise its key executives to create shareholder value and, as
such, today the Board has approved the award of the following
options to Dr Peter Sargent under the Company's existing share
option scheme (the "Scheme"):
1. 1,354,725 Options with
exercise price of 1.55p, being the greater of (i) the average
closing price for the three dealing days immediately preceding the
date of grant; and (ii) the closing price on the dealing day
immediately prior to the date of grant. Half of these Options
vest on award and half six months from the date of award
2. 1,354,725 Options with
exercise price of 2.55p, being the exercise price calculated in (1)
above plus 1p. One third of these Options vest on each
anniversary of the date of award (so none are exercisable
immediately, 33.3% from 6 Feb 2025, 66.7% from 6 Feb 2026 and 100%
from 6 Feb 2027)
3. 1,354,725 Options with
exercise price of 3.55p, being the exercise price calculated in (1)
above plus 2p. These Options vest over the same time periods
as described under (2) above.
All Options can be exercised within
10 years of the date of grant.
Following this issue, the Directors
will hold Options over Ordinary Shares in the Company in accordance
with the table below:
|
Option
holder
|
# Options
|
Exercise
price(p)
|
Date of
expiry
|
|
|
|
|
|
|
P Sargent
|
1,354,725
|
1.55
|
05-Feb-34
|
|
P
Sargent
|
1,354,725
|
2.55
|
05-Feb-34
|
|
P
Sargent
|
1,354,725
|
3.55
|
05-Feb-34
|
|
Total P
Sargent
|
4,064,175
|
|
|
|
|
|
|
|
|
C
Chassagnole
|
322,615
|
6.17
|
23-Mar-25
|
|
C
Chassagnole
|
659,641
|
2.50
|
27-Feb-27
|
|
C
Chassagnole
|
350,000
|
5.35
|
26-Mar-28
|
|
C
Chassagnole
|
267,000
|
3.16
|
26-Mar-29
|
|
C
Chassagnole
|
694,287
|
7.55
|
01-Mar-31
|
|
Total C
Chassagnole
|
2,293,543
|
|
|
|
|
|
|
|
|
J Millen
|
520,000
|
5.35
|
26-Mar-28
|
|
J
Millen
|
400,000
|
3.16
|
26-Mar-29
|
|
J
Millen
|
985,454
|
7.55
|
01-Mar-31
|
|
Total J
Millen
|
1,905,454
|
|
|
In addition, Dr Jim Millen is
interested in 1,884,393 Ordinary Shares (equivalent to
approximately 1.39% of the Company's currently issued share
capital); Dr Christophe Chassagnole is interested in 1,102,723
Ordinary Shares (equivalent to approximately 0.81% of the Company's
currently issued share capital).
The total number of Ordinary Shares in issue
remains unchanged at 135,472,478 Ordinary Shares with voting rights
attached (one vote per Ordinary Share). There are no Ordinary
Shares held in treasury. This total voting rights figure may be
used by shareholders as the denominator for the calculations by
which they will determine whether they are required to notify their
interests in, or a change to their interest in, Physiomics under
the Disclosure and Transparency Rules.
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
The notification below, made in
accordance with the requirements of the EU Market Abuse Regulation,
provides further detail in respect of the transaction as described
above.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Dr Peter Sargent
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
CEO
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Physiomics PLC (the
"Issuer")
|
|
b)
|
LEI
|
213800A71DSZ6ABMTQ91
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over Ordinary
Shares
|
|
|
|
|
Identification code
|
GB00BDR6W943
|
|
|
|
|
b)
|
Nature of the transaction
|
Issue of options
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
1.55 pence
|
1,354,725
|
|
|
|
|
2.55 pence
|
1,354,725
|
|
|
|
|
3.55 pence
|
1,354,725
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
4,064,175 ordinary shares
|
|
|
|
|
- Price
|
Average price of 2.55
pence
|
|
|
|
|
e)
|
Date of the transaction
|
06 February 2024
|
|
f)
|
Place of the transaction
|
London, AIM
|
This announcement is released by Physiomics plc and contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.
Notes to
Editor
About Physiomics
Physiomics plc combines cutting edge
PKPD and QSP modelling and data science techniques, along with deep
biology expertise, to help biotech and pharma companies streamline
their drug development journeys.
Our approach is to derive insight
from all relevant data in order to de-risk decision making and
optimise design research across discovery, pre-clinical and
clinical studies.
Through use of bespoke models and
our proprietary Virtual Tumour technology, the Physiomics team has
informed the development of over 100 commercial projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.